


# There Could Be More to Your Heart Failure

## Ask Your Provider About ATTR-CM



**ATTR-CM** (Amyloidosis with Cardiomyopathy) is a rare, serious, underrecognized, and underdiagnosed type of amyloidosis that affects your heart and is associated with heart failure.<sup>1,2</sup>

### ATTR-CM symptoms may include:



Heart failure with preserved ejection fraction<sup>1</sup>



Irregular heartbeat<sup>3</sup>



Fatigue<sup>4</sup>



Feeling dizzy or lightheaded<sup>4</sup>



Shortness of breath<sup>4,5</sup>



Gastrointestinal issues, such as nausea, diarrhea, or constipation<sup>3,6</sup>



Pain or numbness in your lower back or legs, which may be caused by lumbar spinal stenosis, or narrowing of the lower part of the spine<sup>7</sup>



Decreased or strange tingling sensation or pain in your toes or feet<sup>3,4</sup>



Swelling in your legs or ankles (peripheral edema)<sup>4,8</sup>



Bilateral carpal tunnel syndrome<sup>3,7</sup>

### Want to learn more?

Learn more about how ATTR-CM affects the body through one of the options to the right. Your choice will depend on whether you are using the digital or print version of this piece:

• **CLICK HERE** to go directly to the website

• Visit [YourHeartsMessage.com](https://www.yourheartsmesssage.com)

• Use the QR code:

1. Open your smartphone's camera app
2. Hold your phone so the QR code appears on the screen
3. Click the notification that pops up to open the link



**References:** 1. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. *Circulation*. 2017;135(14):1357-1377. doi:10.1161/CIRCULATIONAHA.116.024438 2. Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. *JACC Heart Fail*. 2019;7(8):709-716. doi:10.1016/j.jchf.2019.04.010 3. Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. *Curr Opin Cardiol*. 2018;33(5):571-579. doi:10.1097/HCO.0000000000000547 4. Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. *Circ Heart Fail*. 2019;12(9):e006075. doi:10.1161/CIRCHEARTFAILURE.119.006075 5. Bishop E, Brown EE, Fajardo J, Barouch LA, Judge DP, Halushka MK. Seven factors predict a delayed diagnosis of cardiac amyloidosis. *Amyloid*. 2018;25(3):174-179. doi:10.1080/13506129.2018.1498782 6. Coelho T, Maurer MS, Suhr OB. THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. *Curr Med Res Opin*. 2013;29(1):63-76. doi:10.1185/03007995.2012.754348 7. Nativi-Nicolau JN, Karam C, Khella S, Maurer MS. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. *Heart Fail Rev*. 2022;27(3):785-793. doi:10.1007/s10741-021-10080-2

# How ATTR-CM Affects the Body



ATTR-CM is a type of amyloidosis with cardiomyopathy that affects your heart (called cardiac amyloidosis). Amyloidosis (pronounced am-uh-loy-doh-sis) is a disease where **abnormal proteins** (called amyloid) build up in certain places in your body, like your liver or heart, and may cause these organs to not work correctly.<sup>1,2</sup>




**Amyloidosis** can affect your whole body or just a certain part of it. It cannot be cured and may get worse over time.<sup>1,3,4</sup>




The 2 most common types of cardiac amyloidosis are **light-chain amyloidosis (AL)** and **ATTR-CM**.<sup>4</sup>

## Here's what happens in your heart with ATTR-CM

Over time, the amyloid buildup in your heart causes it to get thick and stiff. This makes it harder for your heart to pump blood and eventually leads to heart failure.<sup>5</sup>



Healthy heart




Heart with ATTR-CM

**References:** 1. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. *Circulation*. 2017;135(14):1357-1377. doi:10.1161/CIRCULATIONAHA.116.024438 2. Kourelis TV, Gertz MA. Improving strategies for the diagnosis of cardiac amyloidosis. *Expert Rev Cardiovasc Ther*. 2015;13(8):945-961. doi:10.1586/14779072.2015.1069181 3. Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. *Trends Cardiovasc Med*. 2018;28(1):10-21. doi:10.1016/j.tcm.2017.07.004 4. Donnelly JP, Hanna M. Cardiac amyloidosis: an update on diagnosis and treatment. *Cleve Clin J Med*. 2017;84(12 suppl 3):12-26. doi:10.3949/ccjm.84.s3.02 5. Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. *JACC Heart Fail*. 2019;7(8):709-716. doi:10.1016/j.jchf.2019.04.010

# Understand the Signs and Symptoms of ATTR-CM

Many of the symptoms of ATTR-CM are like those of more common causes of heart failure. But did you know that some seemingly unrelated signs and symptoms could be caused by ATTR-CM? Your body may be sending you a message.<sup>1-3</sup>

## ATTR-CM symptoms may include:



These examples are for illustrative purposes only. Signs and symptoms may vary from patient to patient.

**If you have heart failure and experience any of these symptoms, talk to your cardiologist about ATTR-CM. The more your doctor knows about what you are experiencing, the better they can help you get many of the answers you need.**

**References:** 1. Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. *Circ Heart Fail.* 2019;12(9):e006075. doi:10.1161/CIRCHEARTFAILURE.119.006075 2. Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. *Curr Opin Cardiol.* 2018;33(5):571-579. doi:10.1097/HCO.0000000000000547 3. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. *Nat Rev Cardiol.* 2010;7(7):398-408. doi:10.1038/nrcardio.2010.67 4. Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH. Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis. *JAMA.* 2017;318(10):962-963. doi:10.1001/jama.2017.9236 5. Coelho T, Maurer MS, Suhr OB. THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. *Curr Med Res Opin.* 2013;29(1):63-76. doi:10.1185/03007995.2012.754348 6. Rubin J, Alvarez J, Teruya S, et al. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? *Amyloid.* 2017;24(4):226-230. doi:10.1080/13506129.2017.1375908 7. Nativi-Nicolau JN, Karam C, Khella S, Maurer MS. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. *Heart Fail Rev.* 2022;27(3):785-793. doi:10.1007/s10741-021-10080-2 8. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. *Circulation.* 2012;126(10):1286-300. doi:10.1161/CIRCULATIONAHA.111.078915 9. Maurer MS, Elliott P, Merlini G, et al; ATTR-ACT Study Investigators. Design and rationale of the phase 3 ATTR-ACT clinical trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). *Circ Heart Fail.* 2017;10(6):e003815. doi:10.1161/CIRCHEARTFAILURE.116.003815 10. Bishop E, Brown EE, Fajardo J, Barouch LA, Judge DP, Halushka MK. Seven factors predict a delayed diagnosis of cardiac amyloidosis. *Amyloid.* 2018;25(3):174-179. doi:10.1080/13506129.2018.1498782



# Talk to Your Doctor

Advocating for yourself or a loved one with the disease can help you get many of the answers you need

## The road to an ATTR-CM diagnosis can be complex and frustrating<sup>1,2</sup>

Awareness among patients, and even physicians, remains low, which results in ATTR-CM being significantly underdiagnosed.<sup>2,3</sup>

- **Underdiagnosis** and **delayed diagnosis** occur because the symptoms of ATTR-CM mimic those of other more common causes of heart failure<sup>1,4,5</sup>
- Some ATTR-CM patients report visiting up to **5 different doctors** before receiving the correct diagnosis<sup>6</sup>



“ Diagnosis took 11 years. If someone would have known to look, mine could have been diagnosed earlier. ”

In memory of Walt, a passionate advocate (1948-2022)

It's important to talk to your doctor if you suspect ATTR-CM.

### Want to learn more?



Learn more about how ATTR-CM affects the body through one of the options to the right. Your choice will depend on whether you are using the digital or print version of this piece:

- **CLICK HERE** to go directly to the website
- Visit [YourHeartsMessage.com/ask-your-cardiologist](https://YourHeartsMessage.com/ask-your-cardiologist)
- Use the QR code:

1. Open your smartphone's camera app
2. Hold your phone so the QR code appears on the screen
3. Click the notification that pops up to open the link

**References:** 1. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. *Circulation*. 2017;135(14):1357-1377. doi:10.1161/CIRCULATIONAHA.116.024438 2. Rozenbaum MH, Large S, Bhambri R, et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. *Cardiol Ther*. 2021;10(1):141-159. doi:10.1007/s40119-021-00219-5 3. Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. *JACC Heart Fail*. 2019;7(8):709-716. doi:10.1016/j.jchf.2019.04.010 4. Connors LH, Sam F, Skinner M, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. *Circulation*. 2016;133(3):282-290. doi: 10.1161/CIRCULATIONAHA.115.018852 5. Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. *Circ Heart Fail*. 2019;12(9):e006075. doi:10.1161/CIRCHEARTFAILURE.119.006075 6. Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. *Adv Ther*. 2015;32(10):920-928. doi:10.1007/s12325-015-0250-0